We’d love to hear your feedback on this activity. It helps us to continually improve our products.
The ADAPT trial (NCT03669588) supported US Food and Drug Administration approval of efgartigimod alfa-fcab in generalized myasthenia gravis. Dr Francesco Saccà (University of Naples Federico II, Naples, Italy) discussed the findings of the study, in terms of health-related quality-of-life outcomes. Questions: 1. What are the current challenges in managing cases of generalized myasthenia gravis? (00:14) […]
ABCA7 is a major risk gene for Alzheimer’s disease (AD), and rare premature termination codon and missense mutations are enriched in AD patients. Elisabeth Hendrickx Van de Craen (VIB-UAntwerpen, University of Antwerp, Antwerp, Belgium) spoke with touchNEUROLOGY about the findings of her study with patients presenting with cerebral amyloid angiopathy and Alzheimer’s disease, and how […]
Real-world data is an important supplement to evidence gained from clinical trials regarding the use of disease-modifying therapies in multiple sclerosis. In this touchNEUROLOGY interview, Dr Melinda Magyari (University of Copenhagen, Copenhagen, Denmark) shares her thoughts on the benefits of real-world data, how ‘big data’ can help physicians understand treatment characteristics, and the future impact […]
There are currently no disease-modifying medications for the treatment of Huntington’s disease, and current treatment is entirely dependent on symptomatic therapies. Prof. Erin Furr-Stimming (McGovern Medical School, University of Texas, Health Science Centre, Houston, TX, USA) joins touchNEUROLOGY to discuss the current treatment landscape of Huntington’s disease and the limitations of current treatment options. Watch […]
Chorea is a common motor symptom of Huntington Disease (HD) which impacts motor function. Valbenazine, a potent and selective vesicular monoamine transporter 2 inhibitor, is being investigated for the treatment of chorea associated HD, and was approved for the treatment of tardive dyskinesia in the United States in 2017. Prof. Erin Furr-Stimming (McGovern Medical School, […]
In an interview with touchNEUROLOGY, Prof. Heinz Reichmann (University of Dresden Medical School, Germany) gave us his insight into his highlights in Parkinson’s disease, the interventions currently under investigation and how he sees management strategies for Parkinson’s disease evolving in the coming years. Questions: What are your highlights from the Parkinson’s disease scientific sessions at […]
In phase 3 studies, alemtuzumab demonstrated efficacy and safety in patients with relapsing-remitting multiple sclerosis. In an interview with touchNEUROLOGY, Prof. Bart Van Wijmeersch (Universiteit Hasselt and Rehabilitation and MS-Centre Pelt, Belgium) talks through the aims of the alemtuzumab post-authorization safety study, key findings, and insights gained regarding duration of monitoring following treatment with alemtuzumab […]
Opicapone has proved effective for the treatment of end-of-dose motor fluctuations in patients with Parkinson’s disease. Here, Prof. Ray Chaudhuri (King’s College Hospital, London, UK) discusses the effect of disabling fluctuations and dyskinesias on patient quality of life, efficacy and safety of opicapone, and the best way to incorporate this treatment into practice. Questions: For […]
Early detection of Parkinson’s disease can vastly improve outcomes. Prof. Tiago Outiero (University Medical Center Goettingen, Goettingen, Germany) discussed with touchNEUROLOGY his research combining basic science to use biological markers and clinical signs to diagnose Parkinson’s disease. Questions: Why is early detection of Parkinson’s disease essential, and what are the current challenges in achieving this? […]
Get the latest clinical insights from touchNEUROLOGY